S. Moran

发表

Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen

M. Michaelson, P. Corn, D. George, 2014, Clinical Cancer Research.

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

P. Philip, A. Zhu, M. Borad, 2021, The lancet. Gastroenterology & hepatology.

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.

M. Galsky, D. Bajorin, J. Rosenberg, 2020, European urology.

Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model

J. Finnie, J. Bowen, D. Keefe, 2018, Cancer Chemotherapy and Pharmacology.

Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia.

Carole B. Miller, M. Collins, G. Papadakis, 2020, The New England journal of medicine.

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma

M. Galsky, D. Bajorin, J. Rosenberg, 2021, Clinical genitourinary cancer.

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

P. Philip, G. Abou-Alfa, R. Kelley, 2021 .

Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial

G. Abou-Alfa, S. Clarke, E. Hitre, 2019, Annals of Oncology.

Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.

G. Abou-Alfa, S. Clarke, E. Hitre, 2019, Journal of Clinical Oncology.

Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC).

M. Galsky, D. Bajorin, J. Rosenberg, 2020 .

AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions

P. Philip, A. Zhu, M. Borad, 2019, HepatoBiliary Surgery and Nutrition.

Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results

M. Galsky, D. Bajorin, J. Rosenberg, 2020, Cancer.

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea

H. Rugo, L. Bosserman, D. Tripathy, 2019, Breast Cancer Research and Treatment.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

K. Selmaj, A. Coles, D. Margolin, 2008, The New England journal of medicine.

S286: LONG-TERM EFFICACY AND SAFETY RESULTS FROM AN ONGOING OPEN-LABEL PHASE 2 STUDY OF PARSACLISIB FOR THE TREATMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)

A. Patriarca, K. Butler, W. Barcellini, 2022, HemaSphere.

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

P. Wen, T. Cloughesy, N. Butowski, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effective Management and Prevention of Neratinib-Induced Diarrhea

J. D. Palma, C. Saura, R. Bryce, 2015 .

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Sung-Bae Kim, M. Buyse, M. Gnant, 2017, The Lancet. Oncology.

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer

W. Oh, E. Heath, D. Agus, 2015, Investigational New Drugs.

Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial)

F. Saad, J. Nelson, H. Scher, 2014 .

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.

M. Buyse, L. Fallowfield, D. Cella, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial

H. Sullivan, K. Selmaj, A. Coles, 2012, Neurology.

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

K. Selmaj, A. Coles, D. Margolin, 2011, The Lancet Neurology.

Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.

M. Michaelson, P. Corn, D. George, 2012 .

OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study

P. Wen, N. Butowski, J. Raizer, 2019, Neuro-Oncology.

Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC).

W. Oh, E. Heath, D. Agus, 2012 .

Ocular Adverse Effects of Infigratinib, a New FGFR Tyrosine Kinase Inhibitor.

E. FitzGibbon, M. Collins, R. Bishop, 2020, Ophthalmology.

Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.

A. Zhu, M. Borad, G. Abou-Alfa, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis.

Siddharth Singh, M. Pavel, T. Hope, 2023, Journal of Clinical Oncology.

Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.

M. Galsky, D. Bajorin, J. Rosenberg, 2019, Journal of Clinical Oncology.